MDS Clinical Trial
Official title:
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
Status | Recruiting |
Enrollment | 90 |
Est. completion date | May 2025 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients = 18 years of age at the time of obtaining informed consent. - Patients with morphologically documented primary or secondary AML by the World Health Organization(WHO) criteria, whose disease is relapsed/refractory to at least one line of prior therapy, with or without an allogeneic stem cell transplant and for whom no standard therapy that may provide clinical benefit is available or for patients who decline available standard of care. - Patients with a documented diagnosis of high-risk myelodysplastic syndrome (MDS), whose disease is relapsed/refractory, post at least one line of treatment based on the revised International Prognostic Scoring System (IPSS-R) and for whom no standard therapy that may provide clinical benefit is available - Patients are able and willing to comply with study procedures as per protocol, including bone marrowbiopsies. - Patient has an Eastern Cooperative Oncology Group (ECOG) performance status = 2. - Patient must meet the following criteria as indicated on the clinical laboratory tests: oWhite blood cell (WBC) count at the time of the first dose of < 25,000/uL. oAspartate aminotransferase or alanine aminotransferase = 3 × upper limit of normal (ULN; = 5.0× ULN if considered to be due to leukemic involvement). oTotal bilirubin = 2 × ULN (= 3 × ULN if considered to be due to leukemic involvement orGilbert's syndrome). oCreatinine clearance of = 60 mL/min. Exclusion Criteria: - Patient diagnosed with acute promyelocytic leukemia (APL). - Patient has active malignant tumors other than AML/MDS - Patient has had HSCT and meets any of the following: has undergone HSCT within the 6- month period prior to the first study dose; has = Grade 2 persistent non-hematological toxicity related to the transplant donor lymphocytes infusion. - Patient has active graft versus host disease (GVHD) and patients receiving immunosuppressive treatment for GVHD. - Patient with symptomatic central nervous system (CNS) involvement of leukemia or other CNS diseases related to underlying and secondary effects of malignancy - Patient has had major surgery within 4 weeks prior to the first study dose. - Patient has congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patient with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 3 months prior to study entry results in a left ventricular ejection fraction (LVEF) that is = 45%. - Patient has any condition which, in the Investigator's opinion, makes the patient unsuitable for study participation. |
Country | Name | City | State |
---|---|---|---|
United States | Mass. General Hospital-Harvard | Boston | Massachusetts |
United States | Karmanos Cancer Institute | Detroit | Michigan |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | Norton Healthcare-Norton Cancer Institute | Louisville | Kentucky |
United States | Baptist Health South Florida-Miami Cancer Institute | Miami | Florida |
United States | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey |
United States | University of California Irvine Medical Center | Orange | California |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | Virginia Commonwealth University Medical Center | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
PureTech |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Anti-Drug Antibody formation | Assess the immunogenicity of LYT-200 | approximately 1 year | |
Primary | Incidence of Treatment-Emergent Adverse Events [Safety and RP2D determination] | Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status | approximately 1 year | |
Primary | Incidence of Dose Limiting Toxicities [Tolerability and RP2D determination] | Evaluation of tolerability parameters including dose limiting toxicities as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status | approximately 1 year | |
Secondary | Rate of disease responses, time-to-event endpoints, hematological improvements | Evaluate preliminary efficacy of LYT- 200 as a single agent in AML and MDS | approximately 1 year | |
Secondary | Pharmacokinetic (PK) profile of LYT-200_Area Under the Curve (AUC) | Characterize the PK profile of LYT-200 | approximately 1 year | |
Secondary | Pharmacokinetic (PK) profile of LYT-200_Concentration Max (CMax) | Characterize the PK profile of LYT-200 | approximately 1 year | |
Secondary | Pharmacokinetic (PK) profile of LYT-200_Time to Reach CMax (TMax) | Characterize the PK profile of LYT-200 | approximately 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
Recruiting |
NCT03680677 -
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
|
||
Recruiting |
NCT05009537 -
Optical Genome Mapping in Hematological Malignancies
|
||
Not yet recruiting |
NCT04110925 -
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia
|
N/A | |
Terminated |
NCT04638309 -
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
|
Phase 1 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Completed |
NCT02103478 -
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
|
Phase 1/Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
Completed |
NCT00692926 -
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
|
Phase 1 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A | |
Completed |
NCT02214407 -
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
|
Phase 3 | |
Recruiting |
NCT05582902 -
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
|
||
Not yet recruiting |
NCT05024877 -
Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia
|
Phase 2/Phase 3 | |
Completed |
NCT00321711 -
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
|
Phase 2 | |
Recruiting |
NCT06156579 -
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
|
Phase 2 | |
Recruiting |
NCT05226455 -
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
|
Phase 1/Phase 2 | |
Completed |
NCT01690507 -
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML)
|
Phase 1/Phase 2 |